RT期刊文章SR电子T1 NIH注册使用的翼展为symptomatic70 - 99%颅内动脉狭窄支架摩根富林明神经学神经学乔FD Lippincott Williams &威尔金斯SP 1518 OP 1524做wnl.0000306308.08229 10.1212/01首页.。a3签证官70年17 A1 o . o . Zaidat A1 r . Klucznik A1 m·j·亚历山大A1 j . Chaloupka A1 h . Lutsep A1 s Barnwell A1 m . Mawad A1 b巷A1 m·j·林恩A1 m . Chimowitz A1 NIH的多中心翼展颅内支架注册研究小组2008年UL //www.ez-admanager.com/content/70/17/1518.abstract AB背景:Warfarin-Aspirin症状颅内疾病(WASID首页)试验表明,患者症状性颅内动脉狭窄70%到99%的风险特别高侧中风药物治疗:1年18% (95% CI = 3%到24%)。翼展颅内支架是另一种治疗选择,但支架的技术成功有有限的数据和结果的70%到99%狭窄患者治疗的翼展支架。方法:患者连续十六个医疗中心登记翼展支架在这个注册表在2005年11月和2006年10月之间。支架上的数据表明,狭窄的严重程度,技术成功(支架放置在目标病变与< 50%残余狭窄),随访造影,结果被收集。结果:共有129例症状性颅内狭窄为70%至99%。技术的成功率是96.7%。平均前和post-stent狭窄分别为82%和20%。任何频率的中风,脑内出血,30天内死亡或身体的同侧的中风超出30天在6个月时14.0% (95% CI = 8.7%到22.1%)。再狭窄的频率≥50%随访造影是13/52 (25%)。 Conclusion: The use of a Wingspan stent in patients with severe intracranial stenosis is relatively safe with high rate of technical success with moderately high rate of restenosis. Comparison of the event rates in high-risk patients in Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) vs this registry do not rule out either that stenting could be associated with a substantial relative risk reduction (e.g., 50%) or has no advantage compared with medical therapy. A randomized trial comparing stenting with medical therapy is needed. GLOSSARY: FDA = Food and Drug Administration; HDE = Humanitarian Device Exemption; ICH = intracerebral hemorrhage; WASID = Warfarin-Aspirin Symptomatic Intracranial Disease.

map